BACKGROUND: Influenza A has the ability to rapidly mutate and become resistant to the commonly prescribed influenza therapeutics, thereby complicating treatment decisions. OBJECTIVE: To design a cost-effective low-density microarray for use in detection of influenza resistance to the adamantanes. STUDY DESIGN: We have taken advantage of functional genomics and microarray technology to design a DNA microarray that can detect the two most common mutations in the M2 protein associated with adamantane resistance, V27A and S31N. RESULTS: In a blind study of 22 influenza isolates, the antiviral resistance-chip (AVR-Chip) had a success rate of 95% for detecting these mutations. Microarray data from a larger set of samples were further analyzed using an artificial neural network and resulted in a correct identification rate of 94% for influenza virus samples that had V27A and S31N mutations. CONCLUSIONS: The AVR-Chip provided a method for rapidly screening influenza viruses for adamantane sensitivity, and the general approach could be easily extended to detect resistance to other chemotherapeutics.
BACKGROUND:Influenza A has the ability to rapidly mutate and become resistant to the commonly prescribed influenza therapeutics, thereby complicating treatment decisions. OBJECTIVE: To design a cost-effective low-density microarray for use in detection of influenza resistance to the adamantanes. STUDY DESIGN: We have taken advantage of functional genomics and microarray technology to design a DNA microarray that can detect the two most common mutations in the M2 protein associated with adamantane resistance, V27A and S31N. RESULTS: In a blind study of 22 influenza isolates, the antiviral resistance-chip (AVR-Chip) had a success rate of 95% for detecting these mutations. Microarray data from a larger set of samples were further analyzed using an artificial neural network and resulted in a correct identification rate of 94% for influenza virus samples that had V27A and S31N mutations. CONCLUSIONS: The AVR-Chip provided a method for rapidly screening influenza viruses for adamantane sensitivity, and the general approach could be easily extended to detect resistance to other chemotherapeutics.
Authors: Kirsten St George; Navin M Patel; Robert A Hartwig; David R Scholl; Joseph A Jollick; Lynn M Kauffmann; Martin R Evans; Charles R Rinaldo Journal: J Clin Virol Date: 2002-02 Impact factor: 3.168
Authors: Erica D Dawson; Chad L Moore; James A Smagala; Daniela M Dankbar; Martin Mehlmann; Michael B Townsend; Catherine B Smith; Nancy J Cox; Robert D Kuchta; Kathy L Rowlen Journal: Anal Chem Date: 2006-11-15 Impact factor: 6.986
Authors: Darrell P Chandler; Sara B Griesemer; Christopher Knickerbocker; Julia B Golova; Amine Lambarqui; Alexander N Perov; Cynthia Zimmerman; Cory Wiles; George B Rudy; Kirsten St George Journal: J Virol Methods Date: 2014-07-24 Impact factor: 2.014
Authors: Gary L Heil; Troy McCarthy; Kyoung-Jin Yoon; Siyuan Liu; Magdi D Saad; Catherine B Smith; Julie A Houck; Erica D Dawson; Kathy L Rowlen; Gregory C Gray Journal: Influenza Other Respir Viruses Date: 2010-11 Impact factor: 4.380